Tumour Necrosis Factor-alpha and Nuclear Factor-kappa B Gene Variants in Sepsis
| Autor: | Arzu Ergen, E. Hande Karagedik, Nazan Atalan, Leyla Acar |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
0301 basic medicine medicine.medical_specialty Necrosis lcsh:Medicine Inflammation Gastroenterology polymorphism Sepsis 03 medical and health sciences Internal medicine Genotype medicine Humans Allele Gene tumor necrosis factor-alpha Aged business.industry lcsh:R NF-kappa B Sepsis polymorphism tumor necrosis factor-alpha NF-kappa B General Medicine Middle Aged medicine.disease NFKB1 030104 developmental biology Case-Control Studies Female Original Article Tumor necrosis factor alpha medicine.symptom business Polymorphism Restriction Fragment Length |
| Zdroj: | Balkan Medical Journal, Vol 35, Iss 1, Pp 30-35 (2018) Volume: 35, Issue: 1 30-35 Balkan Medical Journal |
| ISSN: | 2146-3131 2146-3123 |
| Popis: | Background: The humoral system is activated and various cytokines are released due to infections in tissues and traumatic damage. Nuclear factor-kappa B dimers are encoded by nuclear factor-kappa B genes and regulate transcription of several crucial proteins of inflammation such as tumour necrosis factor-alpha. Aims: To investigate the possible effect of polymorphisms on tumour necrosis factor-alpha serum levels with clinical and prognostic parameters of sepsis by determining the nuclear factor-kappa B-1-94 ins/del ATTG and tumour necrosis factor-alpha (-308 G/A) gene polymorphisms and tumour necrosis factor-alpha serum levels. Study Design: Case-control study. Methods: Seventy-two patients with sepsis and 104 healthy controls were included in the study. In order to determine the polymorphisms of nuclear factor-kappa B-1-94 ins/del ATTG and tumour necrosis factor-alpha (-308 G/A), polymerase chain reaction–restriction fragment length polymorphism analysis was performed and serum tumour necrosis factor-alpha levels were determined using an enzyme-linked immunosorbent assay. Results: We observed no significant differences in tumour necrosis factor-alpha serum levels between the study groups. In the patient group, an increase in the tumour necrosis factor-alpha serum levels in patients carrying the tumour necrosis factor-alpha (-308 G/A) A allele compared to those without the A allele was found to be statistically significant. Additionally, an increase in the tumour necrosis factor-alpha serum levels in patients carrying tumour necrosis factor-alpha (-308 G/A) AA genotype compared with patients carrying the AG or GG genotypes was statistically significant. No significant differences were found in these 2 polymorphisms between the patient and control groups (p>0.05). Conclusion: Our results showed the AA genotype and the A allele of the tumour necrosis factor-alpha (-308 G/A) polymorphism may be used as a predictor of elevated tumour necrosis factor-alpha levels in patients with sepsis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|